Cwm LLC Increases Stock Position in Boston Scientific Co. (NYSE:BSX)

Cwm LLC grew its stake in Boston Scientific Co. (NYSE:BSX) by 11.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,198 shares of the medical equipment provider’s stock after buying an additional 2,979 shares during the period. Cwm LLC’s holdings in Boston Scientific were worth $1,630,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. FMR LLC grew its stake in Boston Scientific by 6.8% in the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock worth $6,648,595,000 after buying an additional 8,045,263 shares in the last quarter. Vanguard Group Inc. grew its stake in Boston Scientific by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after buying an additional 1,525,432 shares in the last quarter. Wellington Management Group LLP grew its stake in Boston Scientific by 5.9% in the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock worth $2,221,641,000 after buying an additional 2,336,348 shares in the last quarter. Morgan Stanley grew its stake in Boston Scientific by 2.3% in the 3rd quarter. Morgan Stanley now owns 21,200,339 shares of the medical equipment provider’s stock worth $1,119,378,000 after buying an additional 481,891 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Boston Scientific by 0.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 17,207,345 shares of the medical equipment provider’s stock worth $908,548,000 after buying an additional 51,293 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday. Raymond James boosted their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a report on Thursday. Barclays boosted their price objective on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a report on Friday. Finally, UBS Group boosted their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $75.09.

Boston Scientific Trading Down 0.2 %

NYSE:BSX opened at $73.13 on Friday. The company has a 50-day moving average price of $67.82 and a 200-day moving average price of $60.51. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $74.39. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The stock has a market cap of $107.29 billion, a price-to-earnings ratio of 61.45, a P/E/G ratio of 2.48 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The firm had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.59 billion. During the same period last year, the company posted $0.45 EPS. Equities analysts predict that Boston Scientific Co. will post 2.32 EPS for the current year.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the completion of the transaction, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The disclosure for this sale can be found here. Insiders sold a total of 50,979 shares of company stock worth $3,418,529 in the last three months. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.